Hepion Pharmaceuticals Inc (HEPA)

[Fress]

My next moonshot pick.
Recent Picks that netted me millions
20x NVAX
9x PDSB

HEPA is my next pick.

HEPA 120 Million in cash.
HEPA 130 Million market cap.
HEPA 13 employees burned 19 million last year.

Non-Alcoholic Steatohepatitis (NASH) Market To Reach USD 13.38 Billion By 2026

Institutions own majority of the shares after the last offering at $2.00

The company said it has conducted nine individual animal studies of fibrosis and found consistent and statistically significant antifibrotic effects of CRV431 in every one of these studies. Antifibrotic activity has also been observed in previously reported studies conducted by an independent U.K. laboratory that studied explanted liver and lung tissues taken from human donors. Taken together, these animal and human tissue experiments give the company a "great deal of confidence" that CRV431 has beneficial antifibrotic effects that are expected to be borne out clinically.


Former Novo Nordisk Executive, Dr. Todd M. Hobbs, Joins Hepion Pharmaceuticals as Chief Medical Office.r
https://www.biospace.com/article/releases/former-novo-nordisk-executive-dr-todd-m-hobbs-joins-hepion-pharmaceuticals-as-chief-medical-officer/


Showing better results than MDGL at 28 days then MDGL 2 Billion market cap.


HEPA Tackling Chronic Liver Disease - CRV431 Mechanism of Action.

HEPA AI POWR Platform
https://hepionpharma.com/ai-powr/

HEPA website
https://hepionpharma.com


$HEPA